5.4: Who Is the Boss of Global Health?

Apparently Everyone. Also, No One.

Imagine a new infectious disease begins spreading rapidly across several countries. Who is in charge? The World Health Organization? National governments? Scientists? Hospitals? Pharmaceutical companies? Private foundations? NGOs? The communities actually living through the outbreak? The answer is: Yes. Also: Not exactly. Welcome to global health governance, where enormous problems cross borders but authority remains scattered among governments, international organizations, corporations, foundations, researchers, donors, civil-society organizations, and communities. There is no global president. There is no global parliament with unlimited authority. And there is definitely no Global Ministry of Health capable of announcing, “Everybody vaccinate by Friday. Also, please stop creating antibiotic-resistant bacteria.” Instead, global health operates through overlapping systems of law, expertise, financing, negotiation, persuasion, markets, institutions, and occasionally a truly heroic quantity of meetings.That can look chaotic. It is. But it is also one of the clearest examples of how governance works in a globalized world.

The distinction between government and governance matters here. Government refers to formal political authority. Governance is broader: it includes the rules, institutions, financing arrangements, negotiations, relationships, and decision-making processes through which collective problems are managed, even when no single government controls the system. Scholars of global health governance therefore look not only at states and international organizations but also at corporations, foundations, civil society, expert networks, and public-private partnerships (Dodgson et al., 2002; Fidler, 2010; Frenk & Moon, 2013).

If you are looking for one person to blame when the system becomes messy, I regret to inform you that the organizational chart has defeated you.

Figure \(\PageIndex{1}\): Global Governance Without a Global Government. Geneva hosts many institutions involved in international health, yet no single organization governs global health with unlimited authority.  (Photo by Jonathan Ansel Moy de Vitry on Unsplash)

Surely WHO Is in Charge?

If global health had a headquarters, most people would probably point to Geneva. The World Health Organization, established in 1948 as the specialized United Nations agency for international health, collects and analyzes health data, develops technical guidance, coordinates international responses to health emergencies, supports disease surveillance, establishes norms, advises governments, and coordinates major health campaigns. So WHO is the boss? Not quite. WHO exists because sovereign states created it. Its Member States participate in the World Health Assembly, and WHO ordinarily cannot enter a country and simply take over its health ministry. It relies heavily on governments to report outbreaks, cooperate with recommendations, finance activities, and implement health measures. That creates one of the defining tensions of international health: The risks are increasingly global, while much of the strongest political authority remains national (Fidler, 2003; Frenk & Moon, 2013). WHO therefore possesses substantial technical and normative authority, but expertise is not the same thing as unlimited political power. WHO can say: Here is what the evidence indicates governments should do. A government can still respond: Interesting. Money makes that relationship even more complicated. WHO receives both assessed contributions from Member States and voluntary contributions from governments and other donors. Scholars have long examined how reliance on voluntary and earmarked financing can restrict the organization's freedom to allocate resources according to priorities collectively agreed upon by all Member States (Clinton & Sridhar, 2017). The issue is not that voluntary funding is bad. Much of WHO's work depends on it. The issue is that funding structures can become governance structures. If a large share of an institution's money arrives attached to particular diseases, programs, or donor priorities, then questions about institutional independence and agenda setting become unavoidable. Money does not automatically control policy, but pretending money and power have never met would be adorable.

Sovereignty Has Entered the Chat

National governments remain extraordinarily important because they possess capacities international organizations generally do not. Governments can tax, regulate health professionals, purchase medicines, build hospitals, establish insurance systems, control borders, create vaccination policy, regulate food and drugs, and decide whether health care is understood primarily as a public service, a market commodity, an individual responsibility, or some combination of all three. During health emergencies, those powers can collide directly with international cooperation. Imagine a disease emerging inside one country. International institutions want rapid reporting. But the national government may worry that disclosure will trigger travel bans, damage tourism, disrupt trade, frighten investors, or create political consequences at home. Now public health and national interest are pulling in different directions. The International Health Regulations were designed in part to manage precisely this problem by creating shared rules for detecting and responding to health threats that may cross borders (Gostin & Katz, 2016). Yet international law still depends heavily on national implementation. Global risk. National authority. There is our problem.

Science Meets the Extremely Expensive Pill

Then pharmaceutical companies enter the story. Vaccines, antiviral drugs, antibiotics, cancer treatments, diagnostics, and medical devices require scientific expertise, investment, research capacity, manufacturing infrastructure, and often substantial financial risk. Intellectual-property protections such as patents are designed partly to encourage innovation by providing temporary exclusive rights. That arrangement makes some sense. Until the product is lifesaving. If a new sneaker is too expensive, most people can survive without it. If a lifesaving medicine is too expensive, the ethical stakes change considerably.

This creates an enduring tension between innovation and access. Pharmaceutical markets have produced extraordinary advances in human health, but scholars have also shown how intellectual-property rules, manufacturing capacity, market incentives, and purchasing power shape which medicines are developed and who can obtain them (Trouiller et al., 2002; ’t Hoen et al., 2011).

The dilemma is not as simple as “patents good” or “patents evil.” Research incentives matter. So does affordability. Manufacturing matters. So does technology transfer. Market competition matters. So does public investment in research. Global health has a remarkable ability to turn every apparently simple answer into four more questions. The tension becomes especially visible when the people who most need a medicine are also the people least able to create a profitable market for it. This is one reason neglected tropical diseases became such a powerful case in global health: severe disease burdens could coexist with limited commercial incentives for pharmaceutical development (Trouiller et al., 2002). Markets can produce remarkable innovation. Markets can also produce a brutally simple outcome:

If there is no profitable customer, there may be very little market.

Billionaires, But Make It Public Health

Large philanthropic foundations complicate the governance landscape even further. Private philanthropy has financed vaccine programs, infectious-disease research, sanitation initiatives, agricultural interventions, health technologies, and many other public-health efforts. The Bill & Melinda Gates Foundation, in particular, has become one of the most influential private actors in contemporary global health. This funding has supported major health gains. But philanthropy introduces a peculiar democratic question. Imagine someone controls billions of dollars and wants to improve global health. Wonderful. Now ask:

Who elected them?

That does not mean philanthropic foundations should disappear. It means large-scale financial power can translate into agenda-setting power even without formal political authority. Scholars examining philanthrocapitalism have asked how private foundations influence priorities, metrics, research agendas, and institutional behavior through funding choices (McGoey, 2015).

A foundation does not have to pass a law to shape global health. It can fund a disease, a technology, a research network, a university center, a pilot program, or an NGO.The ability to decide what receives money can itself become a form of governance.

And Then We Invented the Hybrid

As if the system were not already complicated enough, global health increasingly operates through public-private partnerships. Take Gavi, the Vaccine Alliance. It brings together governments, WHO, UNICEF, the World Bank, vaccine manufacturers, philanthropic organizations, civil society, and other partners to expand access to immunization. This model reflects a major shift in global governance. Instead of assuming that states and UN agencies must do everything themselves, global health increasingly functions through networks in which different actors contribute different forms of power. Governments may contribute legitimacy and public systems. International organizations bring technical expertise and coordination. Foundations bring financing. Companies bring manufacturing capacity and technology. Civil-society organizations bring community knowledge and advocacy. In theory, everyone contributes what they do best. In practice, they also bring competing priorities, unequal bargaining power, conflicting incentives, and meetings with seventeen logos on the title slide.

The Global Fund to Fight AIDS, Tuberculosis and Malaria offers another version of this hybrid governance model. Its board includes donor governments, implementing countries, civil society, private-sector representatives, foundations, and communities affected by the diseases it funds. That structure is more significant than it may sound. People affected by disease are not supposed to exist only as recipients of programs designed elsewhere. They are supposed to have a role in governing them. That is an important shift in global health thinking. Of course, a seat at the table does not automatically erase inequalities in money, technical expertise, diplomatic influence, language, or institutional status. Representation is not the same thing as equal power. But it changes the architecture.

Sometimes Power Comes From Being Loud

Civil society occupies yet another position in this complicated system. Governments possess law. Corporations possess capital. International organizations possess technical authority. Civil society often possesses pressure. The HIV/AIDS movement demonstrated this vividly. ACT UP activists did not control pharmaceutical companies, government agencies, or international health organizations. Yet they influenced clinical-trial design, regulatory practices, public discussion, medicine access, and the relationship between patients and researchers. That is governance too.

Civil-society organizations can create routes into decision-making for groups excluded from formal institutions. They can organize communities, gather evidence, monitor governments, challenge corporations, deliver services, litigate, advocate, and make politically invisible suffering harder to ignore. But NGOs generate their own questions.

Who funds them?

Who do they actually represent?

Is an international NGO accountable primarily to the community where it works, or to the donor paying for the program?

Why might a large foreign organization have greater influence than a smaller local organization with deeper contextual knowledge?

Good intentions do not make power disappear.

Experts Get a Seat. They Do Not Own the Table.

Modern global health also depends enormously on expertise. Epidemiologists estimate transmission. Economists calculate cost-effectiveness. Clinicians evaluate treatments. Statisticians interpret mortality data. Anthropologists study communities. Data scientists build predictive models.This expertise is essential. But technical knowledge can become politically powerful when decisions are framed as if they contain no values. Suppose a model tells policymakers which intervention saves the most lives per dollar. Useful. But who decided cost per life saved was the only value that mattered? What about historical responsibility? Rights? Geographic fairness? Disability? Community preference? Whether a particular population has been systematically neglected? Evidence can help tell us what a policy is likely to do. Evidence cannot independently decide what society ought to prioritize. Experts deserve a seat at the table. They should not automatically own the table.

Plot Twist: Communities Were Here the Whole Time

Perhaps the most obvious actor in global health is also the one formal institutions have sometimes been surprisingly good at overlooking: the people actually living with the problem. Communities frequently know things external experts do not. They know whether the clinic is really reachable. Whether women feel safe entering it. Whether people trust the government. Whether translated health materials make sense. Whether medicine is being resold informally. Whether public transportation disappears after dark. Whether a beautiful intervention designed somewhere else has any realistic chance of working locally. That knowledge is not anecdotal decoration. It is expertise. This is why contemporary global health increasingly emphasizes local ownership, co-design, community participation, and meaningful engagement. But participation exists on a spectrum. There is a difference between asking: What do you need? and saying: Here is the program we already designed. Would you mind attending the listening session? Participation without decision-making power can become decorative. A genuinely equitable global health system therefore has to ask not only whether communities were consulted, but whether they had meaningful influence over goals, resources, and implementation.

The Accountability Hot-Potato Problem

Once this many actors are involved, another problem appears. What happens when something fails? Imagine an international health program collapses.

The donor says:

We supplied the money.

The international organization says:

We supplied technical guidance.

The pharmaceutical company says:

We manufactured the medicine.

The national government says:

Implementation was decentralized.

The local government says:

We were underfunded.

The NGO says:

We followed the grant requirements.

Everyone played a role.

Somehow nobody owns the failure.

This is one of the central problems of networked governance. Partnerships can mobilize resources and expertise across borders, but complicated institutional arrangements can also blur lines of accountability (Frenk & Moon, 2013). This is especially important when donors favor vertical health programs that focus intensely on one disease or intervention. These programs can be enormously effective. They often have clear goals, measurable outcomes, dedicated expertise, and concentrated financing. But imagine a clinic with no reliable electricity, insufficient staff, poor supply chains, and no transportation system. You can create a brilliant malaria program BUT the clinic is still broken.

That is why scholars have emphasized the importance of balancing disease-specific programs with broader health-system strengthening, including investments in primary care, health workers, laboratories, procurement, financing, infrastructure, and administration (Atun et al., 2008). The political problem is that these long-term investments are often less glamorous.

“We distributed four million bed nets” fits beautifully on a donor report.

“We spent fifteen years improving rural nursing retention, procurement systems, district management, and electrical reliability” is harder to turn into a compelling headline.

Not sexy but extremely important.

Follow the Money. Again.

One of the easiest ways to understand any global health institution is to temporarily ignore its inspirational mission statement and examine its budget.

Who contributes?

Who receives?

Is the money flexible or earmarked?

What outcomes are rewarded?

Which diseases are easier to fund?

Which interventions produce clean metrics?

Which problems require long-term investments that are politically harder to celebrate?

Funding does not merely respond to health problems.

It helps define what the problem is.

A vaccination campaign, a sanitation project, a mental-health system, a hospital, a community-health-worker network, and a housing intervention all represent different theories about what produces health. Budgets reveal those theories surprisingly well. This matters because health problems do not automatically receive global attention in proportion to their severity. Political visibility, advocacy networks, donor priorities, media attention, institutional incentives, and the existence of an appealing solution all shape which issues become global priorities (Shiffman & Smith, 2007). Some problems become urgent. Others become normal. And that brings us to perhaps the most important question in the section: Who gets to set the agenda?

Who Actually Has Power?

A useful way to answer that question is to stop thinking only about formal titles and look at different kinds of power.

One actor may control money. Another controls law. Another controls technology. Another possesses scientific authority. Another controls data. Another has community legitimacy. Another bears the consequences. Those forms of power are not interchangeable. And one of the most revealing questions is: Who can walk away? A government desperate for a vaccine may have less bargaining power than the company that owns the technology. An NGO dependent on one donor may have less room to challenge that donor's priorities. A community dependent on one clinic may have little ability to reject a poorly designed program. Power often belongs partly to the actor who can credibly say: No. That is why global health governance cannot be understood simply by listing organizations. We have to examine the relationships among them.

So Who Is the Boss?

We can finally answer the question that opened this section.

Nobody.

And everybody.

Global health is governed through a complex architecture of states, international organizations, corporations, foundations, partnerships, researchers, NGOs, and communities rather than through a single centralized authority (Fidler, 2010; Frenk & Moon, 2013). That fragmentation can be a strength. Different actors can mobilize science, technology, money, political pressure, legal authority, community knowledge, and logistical capacity. It can produce vaccines, surveillance systems, treatment programs, research collaborations, and genuinely extraordinary global achievements. But fragmentation also creates vulnerabilities. Priorities can follow money. Private actors can influence public goals without the same democratic obligations as governments. Expertise can overshadow local knowledge. Countries with fewer resources can enter negotiations from weaker positions. Communities can be consulted without actually being empowered. And accountability can become extremely difficult to locate. Which leaves us with the question underneath the entire system:

 

When everybody has a seat at the table, who chose the table and who is still standing outside the room?

That question is about to matter enormously. Because COVID-19 did not test one part of the global health system. It stress-tested nearly all of it at once.

Also: Not exactly.

Welcome to global health governance, where enormous problems cross borders but authority remains scattered among governments, international organizations, corporations, foundations, researchers, donors, civil-society organizations, and communities. There is no global president and no global parliament with unlimited authority. There is definitely no Global Ministry of Health capable of announcing, “Everybody vaccinate by Friday. Also, please stop creating antibiotic-resistant bacteria.” Instead, global health operates through overlapping systems of authority, expertise, money, law, negotiation, persuasion, markets, and occasionally a truly heroic quantity of meetings. That can look chaotic. It is. But it is also an excellent example of governance in a globalized world.

Governance is broader than government. It includes the rules, institutions, financing arrangements, negotiations, relationships, and decision-making processes through which collective problems are managed, even where no single government controls the system. Scholars of global health governance therefore examine states alongside international organizations, corporations, philanthropic foundations, civil society, expert networks, and public-private partnerships (Dodgson et al., 2002; Fidler, 2010; Frenk & Moon, 2013).

The most obvious global institution is the World Health Organization, established in 1948 as the specialized United Nations agency for international health. WHO collects and analyzes health data, develops technical guidance, coordinates international responses to health emergencies, supports disease surveillance, establishes norms, advises governments, and coordinates major health campaigns.

So WHO is the boss?

Not quite.

WHO exists because sovereign states created it. Its Member States participate in the World Health Assembly, and the organization ordinarily cannot enter a country and simply take over its health ministry. It depends heavily on governments to report outbreaks, cooperate with recommendations, finance activities, and implement health measures. This produces one of the defining tensions of international health: health risks are increasingly transnational, while much of the strongest political authority remains national (Fidler, 2003; Frenk & Moon, 2013). WHO therefore possesses substantial technical and normative authority. But expertise is not the same thing as unlimited power. WHO can say: Here is what the evidence indicates governments should do. A government can still respond: Interesting.

Money complicates matters further. WHO receives both assessed contributions from Member States and voluntary contributions from governments and other donors. Scholars have long examined how reliance on voluntary and earmarked financing can constrain the organization's freedom to allocate resources according to collectively determined priorities (Clinton & Sridhar, 2017). This does not mean donors simply dictate policy. It does mean that funding structures matter. If much of an institution's financing arrives attached to particular programs or priorities, questions about agenda setting, independence, and accountability become unavoidable. Money and power have, historically, met.

National governments remain extraordinarily important precisely because they possess capacities international institutions often do not. Governments can tax, regulate health professionals, purchase medicines, build hospitals, establish insurance systems, control borders, enact vaccination policies, regulate drugs and food, and decide whether health care is understood primarily as a public service, a market commodity, an individual responsibility, or some combination of all three. During international health emergencies, this creates recurring conflict between cooperation and state sovereignty. A government may be expected to report an outbreak rapidly but fear that disclosure will trigger travel bans, tourism losses, trade disruption, investment decline, or domestic political consequences. The International Health Regulations were designed in part to manage this tension by creating shared rules for detecting and responding to international health threats (Gostin & Katz, 2016). But agreements still depend heavily on national implementation. Global risk. National authority. There is our problem.

Then pharmaceutical companies enter the room. Vaccines, antivirals, antibiotics, cancer treatments, diagnostics, and other medical technologies require expertise, investment, research, and manufacturing capacity. Intellectual-property protections such as patents are designed partly to encourage innovation by providing temporary exclusive rights. But health technologies are not ordinary consumer goods. If a sneaker is too expensive, most people can survive without it. If a lifesaving drug is too expensive, the stakes change. This produces an enduring tension between innovation and access. Scholars studying access to medicines have shown how intellectual-property rules, pharmaceutical markets, manufacturing capacity, and purchasing power influence both which drugs are developed and who can obtain them (Trouiller et al., 2002; ’t Hoen et al., 2011). The debate is more complicated than “patents good” versus “patents evil.” Research incentives matter. So does affordability. Manufacturing capacity matters. So does technology transfer. Global health has a remarkable ability to turn every apparently simple answer into four more questions.

Large philanthropic foundations add another layer. Private philanthropy has supported vaccines, health research, sanitation, infectious-disease programs, health technologies, and numerous other interventions. The Bill & Melinda Gates Foundation, in particular, became a highly influential global health funder. This investment has supported major health gains. It also raises an unusual democratic question. If a private foundation controls billions of dollars capable of altering global priorities: Who elected it?

Scholars examining philanthrocapitalism ask how financial power translates into agenda-setting capacity and whether the preferences of wealthy donors can disproportionately influence public priorities (McGoey, 2015). The question is not whether philanthropy is good or bad. It is whether substantial power should be examined wherever it appears.

Global health has also increasingly moved toward public-private partnerships. Gavi, the Vaccine Alliance, for example, brings together governments, WHO, UNICEF, the World Bank, vaccine manufacturers, philanthropies, civil-society organizations, and others in an effort to expand vaccination access. The Global Fund to Fight AIDS, Tuberculosis and Malaria similarly brings together donor governments, implementing countries, civil society, affected communities, foundations, and private actors. These arrangements reflect an important shift. Instead of assuming governments or UN agencies must solve global health problems alone, governance increasingly operates through networks. Different actors bring different resources. They also bring different incentives. And meetings with seventeen logos on the title slide. Civil-society organizations complicate the picture further because power does not always come from money or law. Sometimes it comes from being loud.

HIV/AIDS activists demonstrated this dramatically. ACT UP did not control a health ministry, pharmaceutical laboratory, or international organization. Yet activists changed clinical-trial practices, public discussion, regulatory processes, and debates over medicine access. That is governance too.

Expertise is another form of power. Epidemiologists model transmission. Economists calculate cost-effectiveness. Clinicians evaluate treatment. Statisticians interpret mortality. Anthropologists investigate local experience. Data scientists model risk. All of this expertise is essential.

But technical knowledge cannot independently determine what societies ought to value. A model can estimate which intervention saves the most lives per dollar. It cannot decide whether historical injustice, disability rights, geographic equity, or community preferences should alter the decision unless someone builds those values into the analysis.

Experts deserve a seat at the table.

They do not automatically own the table.

And then there are communities themselves, the people who actually know whether the clinic is reachable, whether women feel safe entering it, whether the campaign is trusted, whether the translation makes sense, whether transportation disappears after dark, whether medicine is being resold informally, and whether a beautifully designed intervention created in Geneva has any realistic chance of working locally.

Contemporary health practice increasingly emphasizes community participation, local ownership, and co-design.

But there is an enormous difference between:

What do you need?

and

Here is the program we already designed. Would you attend the listening session?

Participation without meaningful authority can become decorative. When global health involves so many actors, another problem emerges: accountability. Imagine a health program fails. The donor says it supplied the money. The international organization says it supplied technical guidance. The company says it manufactured the medicine. The national government says implementation was decentralized. The local authority says it was underfunded. The NGO says it followed the grant requirements. Everyone played a role. Somehow nobody owns the failure. Networks can mobilize enormous resources and expertise, but complicated governance can also blur responsibility (Frenk & Moon, 2013).

This becomes especially important when global donors support narrow disease-specific, or vertical, programs. These can be highly effective: vaccination, malaria prevention, HIV treatment, and other interventions benefit from concentrated expertise, clear goals, and measurable outcomes.

But imagine a rural clinic with no electricity, inadequate staffing, broken procurement systems, and unreliable transportation.

You can create an excellent malaria program.

The clinic is still broken.

This is why scholars have emphasized the need to balance disease-specific interventions with health-system strengthening involving primary care, health workers, supply chains, laboratories, financing, infrastructure, and administration (Atun et al., 2008).

The dilemma is partly political.

“Four million bed nets distributed” fits beautifully on a results dashboard.

“We spent fifteen years improving district procurement, rural nursing retention, electrical reliability, and public administration” is considerably less glamorous.

Not sexy.

Extremely important.

Perhaps the most important question in global health governance is therefore:

Who gets to set the agenda?

Health problems do not automatically receive attention in proportion to suffering. Political visibility, donor interests, advocacy networks, institutional incentives, media coverage, and the availability of attractive solutions can all influence which issues become global priorities (Shiffman & Smith, 2007). Problems have to become politically legible. Someone must frame the issue, produce data, mobilize advocates, secure resources, and convince decision-makers that action is urgent. Sometimes tragedy attracts action. Sometimes tragedy becomes normalized. One useful way to analyze any global health initiative is to follow power. Ask who controls money, law, expertise, technology, data, public legitimacy, and decision-making. Then ask who experiences the consequences and who can walk away. That final question matters enormously. An institution dependent on funding cannot negotiate with a donor on equal terms. A government desperate for medicine may not negotiate with a pharmaceutical company from an equal position. A community dependent on a single NGO for health services may have very little leverage over program design.

Power often belongs partly to the actor who can credibly say:

No.

So who is the boss of global health?

Nobody.

And everybody.

The fragmented system can be a strength. It allows diverse actors to mobilize scientific expertise, money, technology, political pressure, community knowledge, and institutional capacity.

It can also create serious vulnerabilities. Priorities may follow financing. Technical expertise can overshadow local knowledge. Private actors can influence public priorities without the same democratic obligations as governments. Countries with fewer resources may enter negotiations from weaker positions. Communities may be consulted without actually being empowered.

Which leaves us with the question underneath global health governance:

When everybody has a seat at the table, who chose the table and who is still standing outside the room?

COVID-19 would put virtually every part of this system under pressure at once.

And the results were revealing.